An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Dendritic cell vaccine-Immunicum (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms MERECA
- Sponsors Immunicum
- 10 Jun 2017 Biomarkers information updated
- 25 Feb 2017 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.
- 25 Feb 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.